An Open Labelled Prospective Clinical Case Series Study to assess the levels of Microalbuminuria of Diabetic Nephropathy Patients treated with Solidago virgaurea 6CH
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Reduction of urine albumin excretion levels, control of blood glucose levels, Improvement of e-GFR
研究概览
简要总结
Diabetes mellitus is the main cause of end-stage renal disease. Most cases of diabetes mellitus develop into diabetic nephropathy and albuminuria is seen at the time of diagnosis. Microalbuminuria is a clinical sign that indicates vascular damage in the glomerulus which leads to diabetic nephropathy. Microalbuminuria is estimated by the urinary albumin/creatinine ratio, a significant side effect of type II diabetes mellitus is diabetic nephropathy which is characterized by an increased urine albumin excretion rate which eventually results in end-stage renal disease. Hence diabetes mellitus should be monitored regularly for microalbuminuria.
Homeopathic medicines like Helonias, lycopodium, Abroma augusta, Cephalandra indica, Gymnema sylvestre, Syzygium jambolanum, insilin, glycerinum, acid phosphoricum, carbolicum acidum, terebinthinae etc.,
are some of the homeopathic remedies indicated for diabetes. Solidago is effective in the treatment of diabetic nephropathy as it is indicated for albumin, blood, slime in urine, pain in the region of the kidney and kidneys are sensitive to pressure. These are the details that intended me to assess the microalbuminuria levels in diabetic nephropathy patients treated with Solidago virgaurea 6CH by performing a clinical case series study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Not Applicable
- 盲法
- Open Label
入排标准
- 年龄范围
- 20.00 Year(s) 至 70.00 Year(s)(—)
- 性别
- All
入选标准
- •Diabetic Nephropathy patients with ACR value >2.5mg/mmol creatinine in males ACR value >3.5mg/mmol creatinine in females.
排除标准
- •Patients suffering from other renal diseases
- •Gestational diabetic patients
- •Diabetes Mellitus patients with Multi-System Involvement.
结局指标
主要结局
Reduction of urine albumin excretion levels, control of blood glucose levels, Improvement of e-GFR
时间窗: 60 days
Reduction of ACR value
时间窗: 60 days
次要结局
未报告次要终点
